According to Heron Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.92308. At the end of 2022 the company had a P/E ratio of -1.45.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.45 | -64.39% |
2021 | -4.06 | -52.08% |
2020 | -8.47 | -9.91% |
2019 | -9.40 | -10.49% |
2018 | -10.5 | 112.94% |
2017 | -4.93 | 71.3% |
2016 | -2.88 | -68.3% |
2015 | -9.08 | 160.89% |
2014 | -3.48 | 33.44% |
2013 | -2.61 | -57.31% |
2012 | -6.11 | 248.86% |
2011 | -1.75 | -29.93% |
2010 | -2.50 | -36.51% |
2009 | -3.94 | 603.13% |
2008 | -0.5600 | 55.6% |
2007 | -0.3599 | -76.09% |
2006 | -1.51 | -67.53% |
2005 | -4.64 | 18.02% |
2004 | -3.93 | -66.33% |
2003 | -11.7 | 296.67% |
2002 | -2.94 | -86.34% |
2001 | -21.5 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | 25.6 | -1,429.20% | ๐ฎ๐ช Ireland |
![]() | 180 | -9,448.86% | ๐บ๐ธ USA |
![]() | -0.4634 | -75.90% | ๐บ๐ธ USA |
![]() | 68.3 | -3,649.24% | ๐บ๐ธ USA |
![]() | -18.5 | 863.42% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.